Literature DB >> 29595997

Structure and Immune Recognition of the HIV Glycan Shield.

Max Crispin1, Andrew B Ward2, Ian A Wilson2,3.   

Abstract

Vaccine design efforts against the human immunodeficiency virus (HIV) have been greatly stimulated by the observation that many infected patients eventually develop highly potent broadly neutralizing antibodies (bnAbs). Importantly, these bnAbs have evolved to recognize not only the two protein components of the viral envelope protein (Env) but also the numerous glycans that form a protective barrier on the Env protein. Because Env is heavily glycosylated compared to host glycoproteins, the glycans have become targets for the antibody response. Therefore, considerable efforts have been made in developing and validating biophysical methods to elucidate the complex structure of the Env-spike glycoprotein, with its combination of glycan and protein epitopes. We illustrate here how the application of robust biophysical methods has transformed our understanding of the structure and function of the HIV Env spike and stimulated innovation in vaccine design strategies that takes into account the essential glycan components.

Entities:  

Keywords:  EM structure; X-ray structure; broadly neutralizing antibody; glycan composition; glycosylation; viral glycoprotein

Year:  2018        PMID: 29595997      PMCID: PMC6163090          DOI: 10.1146/annurev-biophys-060414-034156

Source DB:  PubMed          Journal:  Annu Rev Biophys        ISSN: 1936-122X            Impact factor:   12.981


  149 in total

1.  Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).

Authors:  P D Kwong; R Wyatt; E Desjardins; J Robinson; J S Culp; B D Hellmig; R W Sweet; J Sodroski; W A Hendrickson
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

Review 2.  Glycobiology.

Authors:  T W Rademacher; R B Parekh; R A Dwek
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

3.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Authors:  Jesper Pallesen; Nianshuang Wang; Kizzmekia S Corbett; Daniel Wrapp; Robert N Kirchdoerfer; Hannah L Turner; Christopher A Cottrell; Michelle M Becker; Lingshu Wang; Wei Shi; Wing-Pui Kong; Erica L Andres; Arminja N Kettenbach; Mark R Denison; James D Chappell; Barney S Graham; Andrew B Ward; Jason S McLellan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

4.  HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.

Authors:  Joseph G Jardine; Daniel W Kulp; Colin Havenar-Daughton; Anita Sarkar; Bryan Briney; Devin Sok; Fabian Sesterhenn; June Ereño-Orbea; Oleksandr Kalyuzhniy; Isaiah Deresa; Xiaozhen Hu; Skye Spencer; Meaghan Jones; Erik Georgeson; Yumiko Adachi; Michael Kubitz; Allan C deCamp; Jean-Philippe Julien; Ian A Wilson; Dennis R Burton; Shane Crotty; William R Schief
Journal:  Science       Date:  2016-03-25       Impact factor: 47.728

5.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.

Authors:  Yuhang Liu; Junhua Pan; Yongfei Cai; Nikolaus Grigorieff; Stephen C Harrison; Bing Chen
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 7.  Separation-based glycoprofiling approaches using fluorescent labels.

Authors:  Paula Jane Domann; Ana Carmen Pardos-Pardos; Daryl Ludger Fernandes; Daniel Ian Richard Spencer; Catherine Mavis Radcliffe; Louise Royle; Raymond Allen Dwek; Pauline Mary Rudd
Journal:  Proteomics       Date:  2007-09       Impact factor: 3.984

8.  Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.

Authors:  Fernando Garces; Jeong Hyun Lee; Natalia de Val; Alba Torrents de la Pena; Leopold Kong; Cristina Puchades; Yuanzi Hua; Robyn L Stanfield; Dennis R Burton; John P Moore; Rogier W Sanders; Andrew B Ward; Ian A Wilson
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

9.  Glycoprotein structural genomics: solving the glycosylation problem.

Authors:  Veronica T Chang; Max Crispin; A Radu Aricescu; David J Harvey; Joanne E Nettleship; Janet A Fennelly; Chao Yu; Kent S Boles; Edward J Evans; David I Stuart; Raymond A Dwek; E Yvonne Jones; Raymond J Owens; Simon J Davis
Journal:  Structure       Date:  2007-03       Impact factor: 5.006

10.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.

Authors:  Laura K Pritchard; David J Harvey; Camille Bonomelli; Max Crispin; Katie J Doores
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

View more
  55 in total

1.  SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Philippe Colin; Jonathan L Torres; Anila Yasmeen; Wen-Hsin Lee; Albert Cupo; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

3.  Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope.

Authors:  Goran Bajic; Max J Maron; Yu Adachi; Taishi Onodera; Kevin R McCarthy; Charles E McGee; Gregory D Sempowski; Yoshimasa Takahashi; Garnett Kelsoe; Masayuki Kuraoka; Aaron G Schmidt
Journal:  Cell Host Microbe       Date:  2019-05-16       Impact factor: 21.023

Review 4.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 5.  Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors:  Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal:  Expert Opin Ther Targets       Date:  2020-04-27       Impact factor: 6.902

Review 6.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

Review 7.  Harnessing post-translational modifications for next-generation HIV immunogens.

Authors:  Joel D Allen; Rogier W Sanders; Katie J Doores; Max Crispin
Journal:  Biochem Soc Trans       Date:  2018-05-21       Impact factor: 5.407

8.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Authors:  Rajesh P Ringe; Pavel Pugach; Christopher A Cottrell; Celia C LaBranche; Gemma E Seabright; Thomas J Ketas; Gabriel Ozorowski; Sonu Kumar; Anna Schorcht; Marit J van Gils; Max Crispin; David C Montefiori; Ian A Wilson; Andrew B Ward; Rogier W Sanders; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

9.  Structural Analysis of the Glycoprotein Complex Avidin by Tandem-Trapped Ion Mobility Spectrometry-Mass Spectrometry (Tandem-TIMS/MS).

Authors:  Fanny C Liu; Tyler C Cropley; Mark E Ridgeway; Melvin A Park; Christian Bleiholder
Journal:  Anal Chem       Date:  2020-02-28       Impact factor: 6.986

10.  Illuminating the virus life cycle with single-molecule FRET imaging.

Authors:  Maolin Lu; Xiaochu Ma; Walther Mothes
Journal:  Adv Virus Res       Date:  2019-08-20       Impact factor: 9.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.